Nanovibronix (NASDAQ:NAOV) Trading Down 4.5% – What’s Next?

Nanovibronix, Inc. (NASDAQ:NAOV) shares traded down 4.5% during mid-day trading on Monday . The company traded as low as $4.01 and last traded at $4.1150. 32,840 shares were traded during trading, an increase of 5% from the average session volume of 31,334 shares. The stock had previously closed at $4.31.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nanovibronix in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Nanovibronix from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Nanovibronix Stock Down 4.5%

The company has a fifty day moving average of $4.66 and a two-hundred day moving average of $6.67. The stock has a market capitalization of $4.49 million, a price-to-earnings ratio of -0.10 and a beta of 2.05.

Nanovibronix (NASDAQ:NAOV) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.91) EPS for the quarter. Nanovibronix had a negative return on equity of 24.78% and a negative net margin of 275.12%.The firm had revenue of $0.72 million for the quarter.

About Nanovibronix

Nanovibronix, Inc is a medical technology company that develops and markets noninvasive, wearable ultrasound devices for therapeutic applications. The company’s core focus lies in wound management and pain relief using its proprietary ultrasonic platform, which delivers low-intensity acoustic energy through lightweight, disposable transducers. Nanovibronix’s products are designed to accelerate tissue repair, reduce inflammation and minimize reliance on pharmaceuticals in both acute and chronic care settings.

The company’s flagship offerings include the Dermacare System for chronic wound therapy and the PainShield System for postoperative pain management.